← All trials
NCT02205931
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Jun 1, 2018
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- University of BirminghamCollaborator
- University of LeedsCollaborator
- University of LiverpoolCollaborator
- University of LondonCollaborator
- Sheffield Hallam UniversityCollaborator
- National Institute for Health Research, United KingdomCollaborator
- University of BristolCollaborator
- University of ManchesterCollaborator
- University of LondonOverall official - principal investigator
- Lancashire Teaching Hospitals NHS Foundation TrustCollaborator
- University of CambridgeCollaborator
- Newcastle UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.